Advertisement

Relation of serum uric acid to cardiovascular disease

      Abstract

      This review summarizes recent published literature on the association between serum uric acid and cardiovascular disease, a relationship which is complex and not fully elucidated. Uric acid may be a marker for risk, a causative agent in cardiovascular disease, or both. Various biologic factors can influence serum uric acid levels, and serum uric acid level itself is closely related to conditions such as hypertension, dyslipidemia, obesity, and impaired glucose metabolism, that contribute to cardiovascular disease pathophysiology. Serum uric acid levels have been found to be associated with adverse outcomes, including mortality, in the general population. In addition, serum uric acid is associated with increased risk for incident coronary heart disease, heart failure, and atrial fibrillation. In the setting of established systolic heart failure, serum uric acid is positively associated with disease severity and mortality risk. Whether targeting treatment based on uric acid levels might affect clinical outcomes is still being studied.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to International Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Brand F.N.
        • McGee D.L.
        • Kannel W.B.
        • Stokes III, J.
        • Castelli W.P.
        Hyperuricemia as a risk factor of coronary heart disease: the Framingham Study.
        Am. J. Epidemiol. 1985; 121: 11-18
        • Rathmann W.
        • Funkhouser E.
        • Dyer A.R.
        • Roseman J.M.
        Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary Artery Risk Development in Young Adults.
        Ann. Epidemiol. 1998; 8: 250-261
        • Fang J.
        • Alderman M.H.
        Serum uric acid and cardiovascular mortality the NHANES I Epidemiologic Follow-up Study, 1971–1992. National Health and Nutrition Examination Survey.
        JAMA. 2000; 283: 2404-2410
        • Niskanen L.K.
        • Laaksonen D.E.
        • Nyyssonen K.
        • et al.
        Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study.
        Arch. Intern. Med. 2004; 164: 1546-1551
        • Culleton B.F.
        • Larson M.G.
        • Kannel W.B.
        • Levy D.
        Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study.
        Ann. Intern. Med. 1999; 131: 7-13
        • Dobson A.
        Is raised serum uric acid a cause of cardiovascular disease or death?.
        Lancet. 1999; 354: 1578
        • Kuzuya M.
        • Ando F.
        • Iguchi A.
        • Shimokata H.
        Effect of aging on serum uric acid levels: longitudinal changes in a large Japanese population group.
        J. Gerontol. A Biol. Sci. Med. Sci. 2002; 57: M660-M664
        • Wannamethee S.G.
        • Shaper A.G.
        • Whincup P.H.
        Serum urate and the risk of major coronary heart disease events.
        Heart. 1997; 78: 147-153
        • Gaffo A.L.
        • Roseman J.M.
        • Jacobs Jr, D.R.
        Serum urate and its relationship with alcoholic beverage intake in men and women: findings from the Coronary Artery Risk Development in Young Adults (CARDIA) cohort.
        Ann. Rheum. Dis. 2010; 69: 1965-1970
        • Choi H.K.
        • Atkinson K.
        • Karlson E.W.
        • Willett W.
        • Curhan G.
        Purine-rich foods, dairy and protein intake, and the risk of gout in men.
        N. Engl. J. Med. 2004; 350: 1093-1103
        • Palmer I.M.
        • Schutte A.E.
        • Huisman H.W.
        Uric acid and the cardiovascular profile of African and Caucasian men.
        J. Hum. Hypertens. 2010; 24: 639-645
        • Voruganti V.S.
        • Nath S.D.
        • Cole S.A.
        • et al.
        Genetics of variation in serum uric acid and cardiovascular risk factors in Mexican Americans.
        J. Clin. Endocrinol. Metab. 2009; 94: 632-638
        • Charles B.A.
        • Shriner D.
        • Doumatey A.
        A genome-wide association study of serum uric acid in African Americans.
        BMC Med. Genomics. 2011; 4: 17
        • Moser M.
        • Feig P.U.
        Fifty years of thiazide diuretic therapy for hypertension.
        Arch. Intern. Med. 2009; 169: 1851-1856
        • Quinones Galvan A.
        • Natali A.
        • Baldi S.
        • et al.
        Effect of insulin on uric acid excretion in humans.
        Am. J. Physiol. 1995; 268: E1-E5
        • Sumino H.
        • Ichikawa S.
        • Kanda T.
        • Nakamura T.
        • Sakamaki T.
        Reduction of serum uric acid by hormone replacement therapy in postmenopausal women with hyperuricaemia.
        Lancet. 1999; 354: 650
        • Watanabe S.
        • Kang D.H.
        • Feng L.
        • et al.
        Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity.
        Hypertension. 2002; 40: 355-360
        • Hare J.M.
        • Johnson R.J.
        Uric acid predicts clinical outcomes in heart failure: insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology.
        Circulation. 2003; 107: 1951-1953
        • Chen J.H.
        • Chuang S.Y.
        • Chen H.J.
        • Yeh W.T.
        • Pan W.H.
        Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study.
        Arthritis Rheum. 2009; 61: 225-232
        • Kivity S.
        • Kopel E.
        • Maor E.
        • et al.
        Association of serum uric acid and cardiovascular disease in healthy adults.
        Am. J. Cardiol. 2013; 111: 1146-1151
        • Forman J.P.
        • Choi H.
        • Curhan G.C.
        Uric acid and insulin sensitivity and risk of incident hypertension.
        Arch. Intern. Med. 2009; 169: 155-162
        • Franse L.V.
        • Pahor M.
        • Di Bari M.
        • et al.
        Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP).
        J. Hypertens. 2000; 18: 1149-1154
        • Hoieggen A.
        • Alderman M.H.
        • Kjeldsen S.E.
        • et al.
        The impact of serum uric acid on cardiovascular outcomes in the LIFE study.
        Kidney Int. 2004; 65: 1041-1049
        • Hamada T.
        • Ichida K.
        • Hosoyamada M.
        • et al.
        Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients.
        Am. J. Hypertens. 2008; 21: 1157-1162
        • Pedersen O.L.
        • Jacobsen F.K.
        • Stengaard-Pedersen K.
        Renal uric acid handling is not affected by beta-adrenoceptor blockade in normotensive subjects.
        Eur. J. Clin. Pharmacol. 1985; 28: 223-224
        • Sihm I.
        • Thygesen K.
        • Krusell L.R.
        • Lederballe O.
        Long-term renal and cardiovascular effects of antihypertensive treatment regimens based upon isradipine, perindopril and thiazide.
        Blood Press. 2000; 9: 346-354
        • Reyes A.J.
        Cardiovascular drugs and serum uric acid.
        Cardiovasc. Drugs Ther. 2003; 17: 397-414
        • Ioachimescu A.G.
        • Brennan D.M.
        • Hoar B.M.
        • Hazen S.L.
        • Hoogwerf B.J.
        Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study.
        Arthritis Rheum. 2008; 58: 623-630
        • Krishnan E.
        • Svendsen K.
        • Neaton J.D.
        • Grandits G.
        • Kuller L.H.
        Long-term cardiovascular mortality among middle-aged men with gout.
        Arch. Intern. Med. 2008; 168: 1104-1110
        • Kojima S.
        • Sakamoto T.
        • Ishihara M.
        • et al.
        Prognostic usefulness of serum uric acid after acute myocardial infarction (the Japanese Acute Coronary Syndrome Study).
        Am. J. Cardiol. 2005; 96: 489-495
        • Killip III, T.
        • Kimball J.T.
        Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients.
        Am. J. Cardiol. 1967; 20: 457-464
        • Ndrepepa G.
        • Braun S.
        • Haase H.U.
        • et al.
        Prognostic value of uric acid in patients with acute coronary syndromes.
        Am. J. Cardiol. 2012; 109: 1260-1265
        • Ekundayo O.J.
        • Dell'Italia L.J.
        • Sanders P.W.
        • et al.
        Association between hyperuricemia and incident heart failure among older adults: a propensity-matched study.
        Int. J. Cardiol. 2010; 142: 279-287
        • Desai R.V.
        • Ahmed M.I.
        • Fonarow G.C.
        • et al.
        Effect of serum insulin on the association between hyperuricemia and incident heart failure.
        Am. J. Cardiol. 2010; 106: 1134-1138
        • Kittleson M.M.
        • St John M.E.
        • Bead V.
        • et al.
        Increased levels of uric acid predict haemodynamic compromise in patients with heart failure independently of B-type natriuretic peptide levels.
        Heart. 2007; 93: 365-367
        • Doehner W.
        • Rauchhaus M.
        • Florea V.G.
        • et al.
        Uric acid in cachectic and noncachectic patients with chronic heart failure: relationship to leg vascular resistance.
        Am. Heart J. 2001; 141: 792-799
        • Anker S.D.
        • Leyva F.
        • Poole-Wilson P.A.
        • Kox W.J.
        • Stevenson J.C.
        • Coats A.J.
        Relation between serum uric acid and lower limb blood flow in patients with chronic heart failure.
        Heart. 1997; 78: 39-43
        • Cicoira M.
        • Zanolla L.
        • Rossi A.
        • et al.
        Elevated serum uric acid levels are associated with diastolic dysfunction in patients with dilated cardiomyopathy.
        Am. Heart J. 2002; 143: 1107-1111
        • Levy W.C.
        • Mozaffarian D.
        • Linker D.T.
        • et al.
        The Seattle Heart Failure Model: prediction of survival in heart failure.
        Circulation. 2006; 113: 1424-1433
        • Wu A.H.
        • Ghali J.K.
        • Neuberg G.W.
        • O'Connor C.M.
        • Carson P.E.
        • Levy W.C.
        Uric acid level and allopurinol use as risk markers of mortality and morbidity in systolic heart failure.
        Am. Heart. J. 2010; 160: 928-933
        • Anker S.D.
        • Doehner W.
        • Rauchhaus M.
        • et al.
        Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging.
        Circulation. 2003; 107: 1991-1997
        • Filippatos G.S.
        • Ahmed M.I.
        • Gladden J.D.
        • et al.
        Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data.
        Eur. Heart J. 2011; 32: 712-720
        • Tamariz L.
        • Agarwal S.
        • Soliman E.Z.
        • et al.
        Association of serum uric acid with incident atrial fibrillation (from the Atherosclerosis Risk in Communities [ARIC] study).
        Am. J. Cardiol. 2011; 108: 1272-1276
        • Valbusa F.
        • Bertolini L.
        • Bonapace S.
        • et al.
        Relation of elevated serum uric acid levels to incidence of atrial fibrillation in patients with type 2 diabetes mellitus.
        Am. J. Cardiol. 2013; 112: 499-504
        • Tamariz L.
        • Hernandez F.
        • Bush A.
        • Palacio A.
        • Hare J.M.
        Association between serum uric acid and atrial fibrillation: a systematic review and meta-analysis.
        Heart Rhythm. 2014; 11: 1102-1108
        • Letsas K.P.
        • Korantzopoulos P.
        • Filippatos G.S.
        • Mihas C.C.
        • Markou V.
        • Gavrielatos G.
        • Efremidis M.
        • Sideris A.
        • Kardaras F.
        Uric acid elevation in atrial fibrillation.
        Hell. J. Cardiol. 2010; 51: 209-213
        • Hirsch G.A.
        • Bottomley P.A.
        • Gerstenblith G.
        • Weiss R.G.
        Allopurinol acutely increases adenosine triphospate energy delivery in failing human hearts.
        J. Am. Coll. Cardiol. 2012; 59: 802-808
        • Doehner W.
        • Schoene N.
        • Rauchhaus M.
        • et al.
        Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies.
        Circulation. 2002; 105: 2619-2624
        • Ogino K.
        • Kato M.
        • Furuse Y.
        Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study.
        Circ. Heart Fail. 2010; 3: 73-81
        • George J.
        • Carr E.
        • Davies J.
        • Belch J.J.
        • Struthers A.
        High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid.
        Circulation. 2006; 114: 2508-2516
        • Hare J.M.
        • Mangal B.
        • Brown J.
        • et al.
        Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study.
        J. Am. Coll. Cardiol. 2008; 51: 2301-2309
        • Givertz M.M.
        • Mann D.L.
        • Lee K.L.
        • et al.
        Xanthine oxidase inhibition for hyperuricemic heart failure patients: design and rationale of the EXACT-HF study.
        Circ. Heart Fail. 2013; 6: 862-868
        • Higgins P.
        • Walters M.R.
        • Murray H.M.
        • et al.
        Allopurinol reduces brachial and central blood pressure, and carotid intima-media thickness progression after ischaemic stroke and transient ischaemic attack: a randomised controlled trial.
        Heart. 2014; 100: 1085-1092
        • Szwejkowski B.R.
        • Gandy S.J.
        • Rekhraj S.
        • et al.
        Allopurinol reduces left ventricular mass in patients with type 2 diabetes and left ventricular hypertrophy.
        J. Am. Coll. Cardiol. 2013; 62: 2284-2293
        • Rekhraj S.
        • Gandy S.J.
        • Szwejkowski B.R.
        • et al.
        High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease.
        J. Am. Coll. Cardiol. 2013; 61: 926-932
        • Levy D.
        • Garrison R.J.
        • Savage D.D.
        • Kannel W.B.
        • Castelli W.P.
        Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study.
        N. Engl. J. Med. 1990; 322: 1561-1566
        • Devereux R.B.
        • Wachtell K.
        • Gerdts E.
        • et al.
        Prognostic significance of left ventricular mass change during treatment of hypertension.
        JAMA. 2004; 292: 2350-2356
        • Sakabe M.
        • Fujiki A.
        • Sakamoto T.
        • Nakatani Y.
        • Mizumaki K.
        • Inoue H.
        Xanthine oxidase inhibition prevents atrial fibrillation in a canine model of atrial pacing-induced left ventricular dysfunction.
        J. Cardiovasc. Electrophysiol. 2012; 23: 1130-1135